

Isolation and Identification of *H. pylori* among Iraqi patients with chronic gastric inflammation

DOI: <https://doi.org/10.32007/jfacmedbagdad.6421929>.

Fatima O. Saber *

BSc

Maryam K. Ali **

MSc, PhD Microbiology



This work is licensed under a [Creative Commons Attribution-NonCommercial 4.0 International License](https://creativecommons.org/licenses/by-nc/4.0/)

Abstract:

Background: *H. pylori* is one of the gastrointestinal organisms in which more than half the world's population is infected. This study aimed to isolate, identify, and determine the antibiotic susceptibility of *H. pylori* from samples of the patient (biopsies) using various procedures.

Patients and methods: A total of 90(58 males, 32females) patients with different age groups from both genders are involved in this study, suffering from dyspeptic symptoms. They underwent diagnostic 'upper' gastrointestinal (G.I.) endoscopy at the Endoscopy unit of AL-Sadder Teaching Hospital in Baghdad, during the period November 2021 to March 2022.

Results: The results showed a relationship between *H. pylori* infection occurrence and endoscopically diagnosed dyspeptic patients; it was recorded that *H. pylori* was isolated in 30 cases. Antibiotic resistance test for *H. pylori* isolates showing susceptibility to levofloxacin, clarithromycin, ciprofloxacin, and amoxicillin. Whereas all the tested isolates appeared resistant to metronidazole and tetracycline.

Conclusion: The results showed a relationship between *H. pylori* infection occurrence and endoscopically diagnosed dyspeptic patients. Culture and antibiotic sensitivity assay for detection of *H. pylori* are more reliable in biopsies than urease tests. *H. pylori* isolates were sensitive to levofloxacin, clarithromycin, ciprofloxacin, and amoxicillin.

Keywords: *Helicobacter pylori*, chronic gastric, biopsy urease test, Antibiotic resistance, Iraqi patients

J Fac Med Baghdad
2022; Vol.64, No. 2
Received: June. 2022
Accepted: June. 2022
Published: July. 2022

Introduction:

Infection with *Helicobacter pylori* (*H. pylori*) is one of the most frequent infections in humans (1). This spiral Gram-negative microaerophilic bacterium enters the stomach and penetrates the mucus gastric layer (2) but does not cross the epithelial barrier, making it a non-invasive bacteria. Although the majority of *H. pylori* organisms live free in the mucus layer, some attach to the apical surface of gastric epithelial cells (3), and a small number have been shown to invade epithelial cells (4).

Antibiotic resistance has recently emerged as a major issue in the treatment of human infectious diseases. This problem also affects the treatment of *Helicobacter pylori* (*H. pylori*) infection, which is still the leading cause of duodenal and peptic ulcers, as well as a risk factor for stomach cancer. Extra-gastric illnesses have been linked to this infection in recent years (5,6). bacterium in the past. The European *Helicobacter* Study Group's recommendations, which include antibiotics such as –lactams,

macrolides, and tetracycline, have been used to eradicate this Polish Society of Gastroenterologists' guidelines recommend treating patients with two or three antibiotics (amoxicillin, clarithromycin, or metronidazole). When *H. pylori* resistance to metronidazole resistance is less than 40%, clarithromycin is less than amoxicillin, and metronidazole clarithromycin or clarithromycin can be used (7,8). Detection of *H. pylori* infection can be made with both invasive and non-invasive tests. Invasive tests include histology, culture, and rapid urease test, which require endoscopy to obtain biopsies of the gastric mucosa, which is expensive and inconvenient. Noninvasive tests, which are based on analysis of samples of breath, blood, or stool, have been developed. (9). Detecting bacterial antigens in stool offers an alternative noninvasive diagnostic test. Its performance in patients has been tested in some developed countries, showing sensitivity and specificity above 90% (10). This research aims to isolate and distinguish *H. pylori* from samples of the patient (biopsies) using various procedures, biochemical tests, culture and antibiotic susceptibility of *H. pylori*.

* Dept. of microbiology, College of Medicine, university of Baghdad.
ftooma.ftooma.ftooma2013@gmail.com

** Dept. of microbiology, College of Medicine, university of Baghdad.
maryam@comed.uobaghdad.edu.iq

Material and Methods:

A total of 90 patients (58 males, and 32 females) of different age groups from both genders were represented, suffering from dyspeptic symptoms. They underwent diagnostic upper gastrointestinal (G.I.) endoscopy at the Endoscopy Unit of AL-Sadder Teaching Hospital in Baghdad during the period November 2021 to March 2022. Several gastric biopsy samples were taken from the stomach cavities. They are subjected to various mucosal examinations, which have also been bacteriological examinations for patients.

Diagnostic Tests (Invasive tests): Biopsy, Urease Test: The test is not final to say as negative until 24 hours, depending on the amount of urease enzyme found in the gastric biopsy. (RUT) with high sensitivity and specificity. Each patient's first biopsy tissue was placed in a tube containing 1 ml of prepared, freshly 10 % urea in distilled water (10 g of urea in 100ml distilled water and pH modified to 6.4), to which 0.002 g of phenol red had been added as a pH indicator. A positive (RUT) result has a deep pink within minutes, and a negative result appears yellow (11, 12).

Direct Biopsy Smear: biopsy samples were crushed, and smears were prepared and stained by routine Gram stain protocols (13).

Biopsy Culturing: biopsy is inoculated in selective (modified Columbia base agar) agar media plates that are used for primary isolation of *H. pylori*. This medium consisted of 44 g Columbia base agar in 1 litre of D.W, which was then dissolved by boiling and autoclaved at 121°C for 15 minutes at 15 pounds/inch². After autoclaving, the medium was chilled to 55°C and supplemented with 5 mg vancomycin, 10 mg amphotericin, 5 mg trimethoprim, and 2500 units polymyxin B, as well as 10 mg hemin and 20 g urea. All of these were sterilized using a Millipore 0.22 mm filter paper, followed mixed thoroughly, and placed into a petri dish, allowing the medium to cool before storage in the refrigerator. The cultures are incubated at 37°C under (5% O₂, 10% CO₂, 85% N₂) micro-aerophilic conditions in an anaerobic jar with a gas-generating kit. Plates are tested for positive growth for intervals of (3-7) days before being rejected as negative. For a positive colony, it must be translucent or grey, tiny, glistening, and covered with entire edges (14, 15).

Biochemical tests

urea ager

Catalase Test

Oxidase Test.

Antibiotic sensitivity test

The method (16) was used to test the sensitivity of 10 isolates of *H. pylori* from biopsy samples to six types of antibiotics.

The test was performed on a pure *H. pylori* culture plate. A colony was placed in the sterile saline solution. Blend by vortexing to ensure that no solid matter from the colony is in the apparent solution. This process frequently even the turbidity of the saline solution appears to match that of the standard turbidity (O.D: 0.5-0.65) into dense check plus. A sterile cotton swab was dipped into the organism's broth culture, and the swab was cultured in each Petri dish containing Muller-Hinton Agar (MHA). The inoculums were spread on the medium in different directions using a sterile cotton swab. Next, streaking the plate was left to dry for five min. Put antibiotic discs on the surface of the agar by using sterilized' forceps. It was incubated for 72 hours at 37° C. After incubation, a metric ruler was used to calculate the diameter of the inhibition zone for every antibiotic used. The measurement got from the antibiotics was compared with the standard table to assign the resistance zone according to CLSI.

Statistics analysis:

Chi-Square test, along with the statistical package (SPSS software version), was used to examine the data (17)

Results:

In the present study, a total of 90 samples, 30 out of 90 patients were positive for RUT, as shown in Table 1 and Figure 1.

Table 1: Distribution of biopsy samples according to the Urea rapid test

Group	No	Percentage (%)
Positive	30	33.3
Negative	60	67.7
Total	90	100%

NS: Non-Significant. P > 0.05

This table shows there is no significant difference between positive and negative urea rapid tests, the p-value >=0.05




Fig 1: Distribution of the sample study according to the rapid Urea test

Table 2: Distribution of biopsy samples according to age group.

Age group	Positive %	Negative	Total
>40	6(28.6)	15(71.4)	21(23.3)
40-50	15(39.6)	31(67.4)	46(51.1)
>50	9(39.1)	14(60.9)	23(25.6)
Total	30(33.3)	60(66.7)	90(100)

P value >0.05

As shown in Table 2, the age group that was subject to this study ranged from (>40->50) years; there was no significant P > 0.05 relationship between age and *H. pylori* infection.

Table 3: Distribution of biopsy samples according to gender

Group	Positive %	Negative (%)
Male	12(40)	46(76.6)
Female	18(60)	14(23.3)
Total	30(100)	60(100)

Significantly different p <= 0.001

A total number of *H. pylori* infection cases subject to the examination of the endoscopy and their distribution among males and females, as shown in Table (3). 12(40%) males showed positive for *H. pylori*, while 18(60%) females showed positive for *H. pylori*. shown in Table (3)




Fig 2: Appear colony of *H. pylori* in modified Columbia base agar (MCBA)

The *H. pylori* isolates showed that antibiotic sensitivity test results were sensitive to levofloxacin, clarithromycin, amoxicillin, and ciprofloxacin. Whereas all isolates were appearing resistant to metronidazole, and tetracycline. As illustrated in the figure (3), figure (4), and table (4)




Fig 3: Antibiotic sensitivity test shows resistance, the sensitivity of *H. pylori* to antibiotics.

Table (4): the prevalence of resistance to antimicrobial agents against *H. pylori* isolates

No. Of Patient	Levofloxacin	Amoxicillin	Metronidazole	Tetracycline	Clarithromycin	Ciprofloxacin
1	Sensitive	Resistant	Resistant	Resistant	Sensitive	Sensitive
2	Sensitive	Intermediate	Resistant	intermediate	Sensitive	intermediate
3	Sensitive	Intermediate	Resistant	intermediate	intermediate	Sensitive
4	Sensitive	Intermediate	Resistant	Resistant	Resistant	Sensitive
5	intermediate	Resistant	Resistant	Resistant	Resistant	Sensitive
6	Sensitive	Sensitive	Resistant	Resistant	intermediate	intermediate
7	Sensitive	Resistant	Resistant	Resistant	Sensitive	Resistant
8	intermediate	Intermediate	Resistant	Resistant	Sensitive	Sensitive
9	Sensitive	Sensitive	Resistant	Resistant	Resistant	Sensitive
10	Sensitive	Resistant	Resistant	Resistant	intermediate	Sensitive
R	0 (0%)	4 (40%)	10 (100%)	8 (80%)	3 (30%)	1 (10%)
S	8 (80%)	2 (20%)	0 (0%)	0 (0%)	4 (40%)	7 (70%)
I	2 (20%)	4 (40%)	0 (0%)	2 (20%)	3 (30%)	2 (20%)
P-	0.0001 **	0.0094 **	0.0001 **	0.0001 **	0.097 NS	0.0001 **

** (P<0.01).




Figure 4: Results of Antibiotics in patients

Discussion:

When a stomach biopsy was taken in the hospital, it was used to diagnose *H. pylori* infection. Table 1 shows that 30 of the 90 patients tested positive for RUT, giving a positive rate of (33.3%). The reason for a positive RUT for *H. pylori* is that it secretes urease, which converts urea, carbon and ammonia to the alkaline indicator phenol red, resulting in a pink colour (18). This result is comparable to that of (19), who obtained 48 out of 120 patients, resulting in a proportion of positives of 48. Rapid urease tests are simple, cheap, and easy, so widely used. The positive bacteria for urease present in the mucosa (staphylococci, streptococci) produce a smaller amount of urease, which does not react in a short time, detection rupture of the method-specific *H. pylori* (20).

In our study, as shown in table 2 patients between 40 to 50 are the most ages group that show higher infection with *H. pylori*, and this result compared with other studies and agrees with (21) shown results that the spread of *H. pylori* 'antibodies among human in the age between 41-50 years were (51.2%), then by the human with age more than sixty-one (>61) years (46.5%), then from 31- 40 years (44.4%) after that from 51-60 years 35.6%, and finally, the age between 21 – 30 years which found just 12/44 infected (27.3%). No significant differences in the *H. pylori* antibodies test between age groups according to positive and negative results ($p>0.05$). In the present study and shown in table 3 female is more than males in the positive result while the male was 66% in the negative' result when compared with females 24% in a negative result which means more, this result agrees with (22) that showed the highest rate of frequency of *H. pylori* antibodies was found in male 65/170(38.2%) while the all most rate of occurrence was found in female 57/140(40.7%), Statistically' the differences in the *H. pylori* antibodies test between male and female according to positive and negative examined were not significant ($p>0.05$). Also, the result was compatible with (23) in Turkey, appear that the male was less exposed to infection with *H. pylori*, *H. pylori* stool antigen test using monoclonal antibodies, and the rate of infection in females was 23.8%, compared with the rate of infection in female 76.2 %. Also, a study by (24) showed no significant difference between males and females of the asymptomatic group; the mean concentration was higher in females than in males. Whereas, in symptomatic patients, the mean concentration was significantly ($p\leq 0.002$) less in males than in females (25). In fact, the difficult process of isolating *H. pylori* from biopsy specimens was due to several factors and the fastidious nature of the bacterium, which is difficult to control, causing difficulty with the culturing of the organism, such as patch distribution of the organism on the gastric mucosa, presence of oropharyngeal flora due to contamination of biopsy forceps, loss of oesophageal flora, and loss. All these

may be responsible for a negative result value associated with a culture of *H. pylori*. As shown in the result, the primary selection media for *H. pylori* isolates appear to be tiny, convex, round, translucent, and smooth colonies. This was similar to (26). *H. pylori* appeared as a Gram-negative spiral form or curved rods on Gram-stained smears. In ancient cultures, *H. pylori* lost its spiral structure and became increasingly coccoid. This may be related to a shortage of critical nutrients. According to prior research, these forms are non-cultivable and nonviable, although others claim that some of them appear non-cultivable, forming a bacterium resistant to antibiotics (27). The positive urease enzyme and oxidase catalase tests declare the presence of *H. pylori* on the culture plates. This is similar to the result produced by (28). The findings of this study contradict those of (29). The susceptibility of 10 isolates of *H. pylori* to six antibiotics. A high percentage of antibiotic resistance, with the ratio of resistance to amoxicillin 70%, metronidazole 100%, ciprofloxacin 50%, clarithromycin 60%, and tetracycline 80%, while the most effective antibiotic for *H. pylori* infection is levofloxacin, which has a high (30). In terms of Metronidazole resistance (100%) of clinical isolates were resistant to that antibiotic; similarly, (19). Amoxicillin resistance was very high (70%), which is similar to the previous study. The overuse of these two antibiotics in *H. pylori* infection may explain these results, as well as ciprofloxacin and clarithromycin, which were also similar to those of (20). The majority of the isolates, on the other hand, had low amoxicillin and tetracycline levels (31). Although levofloxacin remains one of the most widely used second-line antibiotics, bismuth is becoming a more popular option when it is available (32).

Conclusions:

The results showed a relationship between *H. pylori* infection occurrence and endoscopically diagnosed dyspeptic patients. Culture and antibiotic sensitivity assay for the detection of *H. pylori* is more reliable in biopsies than the urease tests. *H. pylori* isolates were sensitive to levofloxacin, clarithromycin, ciprofloxacin, and amoxicillin, whereas all the tested isolates appeared resistant to metronidazole and tetracycline.

Author contributions:

Both Fatima Omer Saber and Maryam Kareem Ali collaborated equally during the experimental works and discussed the results. All authors have accepted and read the published version of the manuscript.

References:

1. Marshall B, Warren JR. Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. *Lancet*. 1984;323(8390):1311-5. [https://doi.org/10.1016/S0140-6736\(84\)91816-6](https://doi.org/10.1016/S0140-6736(84)91816-6)
2. Schreiber S, Konradt M, Groll C, Scheid P, Hanauer G, Werling H-O, et al. The spatial orientation of *Helicobacter pylori* in the gastric mucus. *Proc Natl Acad Sci*. 2004;101(14):5024-9. <https://doi.org/10.1073/pnas.0308386101>
3. Hazell SL, Lee A, Brady L, Hennessy W. *Campylobacter pyloridis* and gastritis: association with intercellular spaces and adaptation to an environment of mucus as important factors in colonization of the gastric epithelium. *J Infect Dis*. 1986;153(4):658-63. <https://doi.org/10.1093/infdis/153.4.658>
4. Semino-Mora C, Doi SQ, Marty A, Simko V, Carlstedt I, Dubois A. Intracellular and interstitial expression of *Helicobacter pylori* virulence genes in gastric precancerous intestinal metaplasia and adenocarcinoma. *J Infect Dis*. 2003;187(8):1165-77. <https://doi.org/10.1086/368133>
5. Budzyński J. The favourable effect of *Helicobacter pylori* eradication therapy in patients with recurrent angina-like chest pain and non-responsive to proton pump inhibitors-a preliminary study. *Arch Med Sci AMS*. 2011;7(1):73. <https://doi.org/10.5114/aoms.2011.20607>
6. Hosseinzadeh M, Khosravi A, Saki K, Ranjbar R. Evaluation of *Helicobacter pylori* infection in patients with common migraine headache. *Arch Med Sci AMS*. 2011;7(5):844. <https://doi.org/10.5114/aoms.2011.25560>
7. Malfertheiner P, Megraud F, O'Morain CA, Atherton J, Axon ATR, Bazzoli F, et al. Management of *Helicobacter pylori* infection-the Maastricht IV/Florence consensus report. *Gut*. 2012;61(5):646-64. <https://doi.org/10.1136/gutjnl-2012-302084>
8. Dzieniszewski J, Jarosz M. The Polish Society of Gastroenterology *Helicobacter pylori* Working Group for the *Helicobacter pylori* infection: Consensus of the Polish Society of Gastroenterology *Helicobacter pylori* Working Group on diagnostic and therapeutic approaches for the *Helicobacter pylori* infection (2008). *Gastroenterol Pol*. 2008;5:323-31.
9. Huang J-J, Huang C-J, Ruaan M-K, Chen K-W, Yen T-S, Sheu B-S. Diagnostic efficacy of 13 C-urea breath test for *Helicobacter pylori* infection in hemodialysis patients. *Am J kidney Dis*. 2000;36(1):124-9. <https://doi.org/10.1053/ajkd.2000.8284>
10. Raguza D, Granato CFH, Kawakami E. Evaluation of the stool antigen test for *Helicobacter pylori* in children and adolescents. *Dig Dis Sci*. 2005;50(3):453-7. <https://doi.org/10.1007/s10620-005-2457-4>
11. Chomvarin C, Kulsantiwong P, Chantarasuk Y, Chantrakooptungoo S, Kanjanahareutai S. Comparison of media and antibiotic supplements for isolation of *Helicobacter pylori* from gastric biopsies. *Southeast Asian J Trop Med Public Health*. 2006;37(6):1163.
12. Braden B. Diagnosis of *Helicobacter pylori* infection. *BMJ*. 2012;344. <https://doi.org/10.1136/bmj.e828>
13. Vijaya D, Chandrashekar N, Nagarantnamma T, Shivarudrappa AS. Simple stain for *Helicobacter pylori*. *J Clin Diag Res*. 2012;6(4):664-6.
14. Piccolomini R, Di Bonaventura G, Festi D, Catamo G, Laterza F, Neri M. Optimal combination of media for primary isolation of *Helicobacter pylori* from gastric biopsy specimens. *J Clin Microbiol*. 1997;35(6):1541-4. <https://doi.org/10.1128/jcm.35.6.1541-1544.1997>
15. Nordenstedt H, Graham DY, Kramer JR, Rugge M, Verstovsek G, Fitzgerald S, et al. *Helicobacter pylori*-negative gastritis: prevalence and risk factors. *Am J Gastroenterol*. 2013;108(1):65. <https://doi.org/10.1038/ajg.2012.372>
16. Khan ZA, Siddiqui MF, Park S. Current and emerging methods of antibiotic susceptibility testing. *Diagnostics*. 2019;9(2):49. <https://doi.org/10.3390/diagnostics9020049>
17. Cary N. *Statistical Analysis System, User's Guide. Statistical. Version 9. SAS. Inst. Inc USA*. 2012;
18. Uotani T, Graham DY. Diagnosis of *Helicobacter pylori* using the rapid urease test. *Ann Transl Med*. 2015;3(1).
19. Rimbara E, Suzuki M, Matsui H, Nakamura M, Morimoto M, Sasakawa C, et al. Isolation and characterization of *Helicobacter suis* from the human stomach. *Proc Natl Acad Sci*. 2021;118(13). <https://doi.org/10.1073/pnas.2026337118>
20. Chen Y, Blaser MJ. Association between gastric *Helicobacter pylori* colonization and glycated hemoglobin levels. *J Infect Dis*. 2012;205(8):1195-202. <https://doi.org/10.1093/infdis/jis106>
21. Al-Mashhadany DA, Ismael LQ, Zaki AM. Seroprevalence of *Helicobacter pylori* among humans in Erbil governorate, Kurdistan region, Iraq.

- Res J Life Bioinform Pharm Chem Sci. 2018;4(2):268-80.
22. Al-Mashhadany DA. Application of stool antigen test for monitoring *Helicobacter pylori* among humans in Erbil governorate, Kurdistan region/Iraq. *Int J Pharm Pharm Sci.* 2018;10(11):49-53. <https://doi.org/10.22159/ijpps.2018v10i11.28872>
23. Yucel T, Aygin D, Sen S, Yucel O. The prevalence of *Helicobacter pylori* and related factors among university students in Turkey. *Jpn J Infect Dis.* 2008;61(3):179. <https://doi.org/10.7883/yoken.JJID.2008.179>
24. Al Saadi KA, Shelab AH, AlKateb MBS. *Helicobacter pylori* CagA antigen detection in patients and its association with the severity of disease in Iraq. 2018; <https://doi.org/10.37623/SJMR.2018.2603>
25. Grove DI, Koutsouridis G, Cummins AG. Comparison of culture, histopathology and urease testing for the diagnosis of *Helicobacter pylori* gastritis and susceptibility to amoxicillin, clarithromycin, metronidazole and tetracycline. *Pathology.* 1998;30(2):183-7. <https://doi.org/10.1080/00313029800169206>
26. Ieni A, Barresi V, Rigoli L, Fedele F, Tuccari G, Caruso RA. Morphological and cellular features of innate immune reaction in *Helicobacter pylori* gastritis: a brief review. *Int J Mol Sci.* 2016;17(1):109. <https://doi.org/10.3390/ijms17010109>
27. Kusters JG, Gerrits MM, Van Strijp JA, Vandenbroucke-Grauls CM. Coccoid forms of *Helicobacter pylori* are the morphologic manifestation of cell death. *Infect Immun.* 1997;65(9):3672-9. <https://doi.org/10.1128/iai.65.9.3672-3679.1997>
28. Davood E, Ashraf MM, Hatef SA, Hosseini Z. Optimization of *Helicobacter pylori* culture to prepare favorable antigens. *J Bacteriol Res.* 2009;1(9):101-4.
29. Baqir GK, Al-Sulam AA, Hamadi SS. Bacteriological and Molecular Study of *Helicobacter pylori* among Patients with Various Gastrointestinal Symptoms in Relation to ABO, Lewis Blood Group Antigens, and Secretor Status. Ph. D thesis, College of Education for Pure Sciences, University of Basrah; 2014.
30. Kouitcheu Mabeku LB, Eyoun Bille B, Tepap Zennou C, Tali Nguefack LD, Leundji H. Broad-spectrum resistance in *Helicobacter pylori* isolated from gastric biopsies of patients with dyspepsia in Cameroon and efflux-mediated multidrug resistance detection in MDR isolates. *BMC Infect Dis.* 2019;19(1):1-11. <https://doi.org/10.1186/s12879-019-4536-8>
31. Shiota S, Reddy R, Alsarraj A, El-Serag HB, Graham DY. Antibiotic resistance of *Helicobacter pylori* among male United States veterans. *Clin Gastroenterol Hepatol.* 2015;13(9):1616-24. <https://doi.org/10.1016/j.cgh.2015.02.005>
32. Althahab AO, Al Abbasy DM, Mzedawee AH, Al Abbasy ZG. ISOLATION, IDENTIFICATION AND ANTIMICROBIAL SUSCEPTIBILITY OF *H. PYLORI* FROM CLINICAL SAMPLES IN BABYLON CITY, IRAQ.

عزل وتشخيص لبكتريا المعدة الملوية البوابية بين مرضى العراق المصابين بالتهاب المعدة المزمن

فاطمة عمر صابر (بكالوريوس علوم حياة \ كلية العلوم \ جامعة بغداد)
الاستاذ مساعد الدكتور مريم كريم علي (دكتوراه احياء مجهرية طبية \ كلية الطب \ جامعة بغداد)
الخلاصة:

خلفية البحث: تعتبر بكتريا المعدة الملوية البوابية أحد الكائنات الحية المعدية المعوية التي أصيب فيها أكثر من نصف سكان العالم ، وكان الهدف من هذه الدراسة هو عزل وتحديد وحساسية المضادات الحيوية لبكتريا الملوية البوابية من عينات المرضى (الخرعات) باستخدام إجراءات مختلفة. **المواد وطرق العمل:** 90 مريضاً (58 رجلاً و 32 أنثى) من مختلف الفئات العمرية من كلا الجنسين يعانون من أعراض عسر الهضم ، وخضعوا للتنظير "العلوي" للجهاز الهضمي في "وحدة التنظير في مستشفى الصدر التعليمي في بغداد. " خلال الفترة من نوفمبر 2021 إلى مارس 2022. **النتائج:** أظهرت النتائج وجود علاقة بين حدوث عدوى الحلزونية البوابية ومرض عسر الهضم المشخصين بالتنظير. وقد تم تسجيل أن الحلزونية البوابية كانت عزل 30 حالة. أظهر اختبار مقاومة المضادات الحيوية لعزلات الحلزونية البوابية القابلة للبيروفلوكساسين والكلاريثروميسين والسيبروفلوكساسين والأموكسيسيلين ، بينما أظهرت جميع العزلات المختبرة مقاومة للميترونيدازول والتتراسيكلين. **الاستنتاجات:** اختبار الزرع وفحص الحساسية للمضادات الحيوية للكشف عن بكتريا الحلزونية البوابية أكثر دقة في عينة الخزعة من اختبار البورياز. كانت جميع العزلات التي تم اختبارها حساسة للبيروفلوكساسين والكلاريثروميسين والسيبروفلوكساسين والأموكسيسيلين بينما وجدت جميع العزلات المختبرة مقاومة لميترونيدازول والتتراسيكلين **مفتاح الكلمات:** بكتريا المعدة الحلزونية البوابية "المعدة المزمنة" اختبار البورياز ، مقاومة المضادات الحيوية. المرضى العراقيين